HBsAg Loss/Seroconversion in Low Replicative Chronic Hepatitis B Virus(HBV) Infection Patients

• Status: Unknown status
• Trial end date: 2019-09-01
• Target enrollment: 0
• Participant gender: All

Summary

HBsAg Loss/Seroconversion is uncommon in Low replicative chronic HBV infection patients. The purpose of this study is to investigate the ability of peginterferon alpha to achieve HBsAg loss/seroconversion therapy in Low replicative chronic HBV infection patients with Low Level HBsAg.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Third Affiliated Hospital, Sun Yat-Sen University
• Collaborators: First People's Hospital of Foshan; First People's Hospital, Shunde China; Huazhong University of Science and Technology; Huizhou Municipal Central Hospital; Nanchang University; Peking University; Shenzhen Third People's Hospital; Tang-Du Hospital; The First Affiliated Hospital of Kunming Medical College; Yuebei People's Hospital
• Treatments: Interferon-alpha; Peginterferon alfa-2a; Peginterferon alfa-2b

Criteria

Inclusion Criteria:

1. Hepatitis B surface antigen (HBsAg) positive and <1000 IU/mL.

2. Hepatitis B surface antibody (HBsAb) negative.

3. Hepatitis B e antigen (HBeAg) negative.

4. Hepatitis B virus DNA <2000 IU/mL.

5. Absence of previous antiviral therapy.

Exclusion Criteria:

1. Patients with active alcohol and/or drugs consumption.

2. Patients with liver cirrhosis, Hepatocellular Carcinoma or other malignancies.

3. Patients with other factors causing liver diseases.

4. Pregnant and lactating women.

5. Patients with concomitant HIV infection or congenital immune deficiency diseases.

6. Patients with diabetes, autoimmune diseases.

7. Patients with important organ dysfunctions.

8. Patients with mental illness.

9. Patients who receive antineoplastic or immunomodulatory therapy in the past 12 months.

10. Patients who can't come back to clinic for follow-up on schedule.